Richard A. Feelders

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

Medicine, Oncology, Pharmacology +15

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Tessa Brabander, Wouter A. van der Zwan, Jaap J.M. Teunissen et al. · Clinical Cancer Research · 2017 · 604 citations

Medicine, Oncology, Pharmacology +17

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 422 citations · Full text

Medicine, Nuclear Medicine, Oncology +10

The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics

Elena Valassi, Alicia Santos, Maria Yaneva et al. · European Journal of Endocrinology · 2011 · 392 citations · Full text

Medicine, Endocrinology, Internal Medicine +11